Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975111 · ClinicalTrials.gov registry record · Phase 2
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
A Phase 2 study, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT06975111 is a Phase 2 study that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 200 participants.
The verdict
NCT06975111, a Phase 2 study, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.
Interventions
- DRUG Metformin
- DRUG semaglutide
- DRUG Anti-hypertensives
- DRUG Lipid Lowering Medication
- BEHAVIORAL Life style intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2030-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06975111
The ClinicalTrials.gov registry entry for NCT06975111 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT06975111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06975111 about?
NCT06975111 is a clinical study titled "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health". What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic pr...
What is the current status of trial NCT06975111?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-03-01. Estimated completion is 2030-10-01.
What interventions are being tested in trial NCT06975111?
The interventions under investigation include: Metformin (DRUG), semaglutide (DRUG), Anti-hypertensives (DRUG), Lipid Lowering Medication (DRUG), Life style intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06975111?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.